Demographics and disease will continue to drive venture capital into biotechnology over the long term despite weaker post-COVID-19 activity
Since 2022, the proportion of biotech exits in VC has almost doubled in value terms to 38%.
Biotechnology still dominates healthcare VC by AUM, but has seen a greater drop-off in fundraising since 2021.
Deal-making appears more resilient but is still to see a recovery from the recent peak in 2021, when 2,527 deals were valued at a total of $70.3bn.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, aliquip ex ea commodo consequat. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, aliquip ex ea commodo consequat. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, aliquip ex ea commodo consequat. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, aliquip ex ea commodo consequat. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, aliquip ex ea commodo consequat.